Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine.
A Li, V M Yuen, S Goulay-Dufaÿ...
https://pubmed.ncbi.nlm.nih.gov/29661413/Actively Recruiting
Led by Suez Canal University · Updated on 2026-04-07
126
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are evaluating whether intranasal dexmedetomidine can help control blood pressure in elderly patients with controlled hypertension undergoing cataract surgery. This phase 3, randomized, double-blind clinical trial aims to reduce fluctuations in mean arterial blood pressure MAP during the perioperative period. The study also assesses secondary outcomes such as surgery cancellation rates and satisfaction levels among patients, anesthesiologists, and surgeons using sedation scales. Participants will be randomly assigned to receive either intranasal dexmedetomidine at a dose of 1 mcgkg ideal body weight or a placebo of normal saline. The medication or placebo will be administered 30 minutes before surgery using a mucosal atomization device, delivering 0.5 mL into each nostril while the patient is semi-recumbent. Local anesthesia will be given through a peribulbar block with lidocaine and bupivacaine by an experienced anesthesiologist under aseptic conditions. During the study, researchers will monitor mean arterial blood pressure, heart rate, and oxygen saturation from before surgery until two hours afterward. They will also record surgery cancellation rates, sedation scores, and satisfaction assessments from patients, anesthesiologists, and surgeons. Surgical duration and hospital stay will be documented to evaluate the interventions effects comprehensively. The total participation duration spans from preoperative baseline through the immediate postoperative period.
CONDITIONS
Intranasal Dexmedetomidine on Blood Pressure in Elderly Hypertensive Patients Undergoing Cataract Surgery
M
Mohammad E Salama, MD
A
Abdelrhman M Alshawadfy, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Suez Canal University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Day of surgery
Participants receive intranasal dexmedetomidine or placebo 30 minutes before cataract surgery under local anesthesia.
1 visit (in-person) on surgery day
Duration - Up to 2 hours postoperatively
Participants are monitored for blood pressure, sedation, heart rate, and satisfaction up to 2 hours after surgery.
1 post-operative visit (in-person)
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
A Li, V M Yuen, S Goulay-Dufaÿ...
https://pubmed.ncbi.nlm.nih.gov/29661413/Xianfei Xu, Yunfei Cao, Youhua Wu...
https://pubmed.ncbi.nlm.nih.gov/34838503/Shaopeng Liu, Ye Wang, Yong Zhu...
https://pubmed.ncbi.nlm.nih.gov/31114165/Lee A Fleisher, Kirsten E Fleischmann, Andrew D Auerbach...
https://pubmed.ncbi.nlm.nih.gov/25085962/Kun Wang, Mengge Wu, Jian Xu...
https://pubmed.ncbi.nlm.nih.gov/31668347/Rui Fang, Yang-Fan Yu, En-Jie Li...
https://pubmed.ncbi.nlm.nih.gov/36369026/Suez Canal University
Lead Sponsor